Literature DB >> 9778165

Importance of the surveillance method: national prevalence studies on nosocomial infections and the limits of comparison.

P Gastmeier1, G Kampf, N Wischnewski, M Schumacher, F Daschner, H Rüden.   

Abstract

OBJECTIVE: To demonstrate the limits of comparison of national prevalence rates of nosocomial infections. DESIGN AND
SETTING: Critical analysis of prevalence rates and methods of the Nosocomial Infections in Germany (NIDEP) study and other prevalence surveys with particular attention to the selection of patients, the qualification and training of the investigators, and the methods of identifying nosocomial infections.
RESULTS: The lowest prevalence rate was found in Germany (3.5%), the highest in Belgium (9.3%). These differences may not be accurate, because variations in methods allow for differing explanations.
CONCLUSIONS: Because of numerous methodological factors, comparison of infection rates between countries should be avoided. In contrast to other prevalence studies, the methodology of the German-NIDEP study permits registration of only certain infections, which is the main reason for the low rate.

Entities:  

Mesh:

Year:  1998        PMID: 9778165     DOI: 10.1086/647895

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  8 in total

Review 1.  Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs.

Authors:  Günter Kampf; Axel Kramer
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

2.  Nosocomial infection and antibiotic use: a second national prevalence study in Germany.

Authors:  Michael Behnke; Sonja Hansen; Rasmus Leistner; Luis Alberto Peña Diaz; Alexander Gropmann; Dorit Sohr; Petra Gastmeier; Brar Piening
Journal:  Dtsch Arztebl Int       Date:  2013-09-20       Impact factor: 5.594

3.  [Electronic surveillance of nosocomial infections in head and neck surgery and stapes surgery].

Authors:  S Preyer; A Failenschmid; M Holderried; D Bless
Journal:  HNO       Date:  2005-04       Impact factor: 1.284

4.  Evaluation of the national surveillance system for point-prevalence of healthcare-associated infections in hospitals and in long-term care facilities for elderly in Norway, 2002-2008.

Authors:  Agnes Hajdu; Hanne M Eriksen; Nina K Sorknes; Siri H Hauge; Hege L Loewer; Bjørn G Iversen; Preben Aavitsland
Journal:  BMC Public Health       Date:  2011-12-13       Impact factor: 3.295

5.  Considerations for a WHO European strategy on health-care-associated infection, surveillance, and control.

Authors:  Didier Pittet; Benedetta Allegranzi; Hugo Sax; Luigi Bertinato; Ercole Concia; Barry Cookson; Jacques Fabry; Hervé Richet; Pauline Philip; Robert C Spencer; Bernardus Wk Ganter; Stefano Lazzari
Journal:  Lancet Infect Dis       Date:  2005-04       Impact factor: 25.071

6.  Concordance between European and US case definitions of healthcare-associated infections.

Authors:  Sonja Hansen; Dorit Sohr; Christine Geffers; Pascal Astagneau; Alexander Blacky; Walter Koller; Ingrid Morales; Maria Luisa Moro; Mercedes Palomar; Emese Szilagyi; Carl Suetens; Petra Gastmeier
Journal:  Antimicrob Resist Infect Control       Date:  2012-08-02       Impact factor: 4.887

7.  High proportion of healthcare-associated urinary tract infection in the absence of prior exposure to urinary catheter: a cross-sectional study.

Authors:  Ilker Uçkay; Hugo Sax; Angèle Gayet-Ageron; Christian Ruef; Kathrin Mühlemann; Nicolas Troillet; Christiane Petignat; Enos Bernasconi; Carlo Balmelli; Andreas Widmer; Karim Boubaker; Didier Pittet
Journal:  Antimicrob Resist Infect Control       Date:  2013-02-07       Impact factor: 4.887

8.  Prevalence of nosocomial infections and anti-infective therapy in Benin: results of the first nationwide survey in 2012.

Authors:  Théodora Angèle Ahoyo; Honoré Sourou Bankolé; Franck Mansour Adéoti; Aimé Attolou Gbohoun; Sibylle Assavèdo; Marcellin Amoussou-Guénou; Dorothée Akoko Kindé-Gazard; Didier Pittet
Journal:  Antimicrob Resist Infect Control       Date:  2014-05-14       Impact factor: 4.887

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.